GENO: Genovis AB (publ.) - Summary | Jitta

Genovis AB (publ.)

SWE:GENO

Price
kr20.45
Loss Chance
47.5%
5.41JITTA SCORE
149.38%Over Jitta Line
Jitta Ranking
53 / 107
404 / 616
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (69)
Recent Business Performance (72)
Financial Strength (90)
Return to Shareholders (23)
Competitive Advantage (45)
Jitta Signs
Revenue and EarningConsistent Growth in the past 5 years
Recent Business PerformanceEarning Growth Last Quarter (YoY)
Debt LevelLow Long Term Debt
SG&A to SalesDecreasing
Operating MarginInconsistent
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
5.41
149.38%
2.89
152.39%
Life Sciences Tools and Services
5.71
226.12%
1.91
100.00%
2.37
100.00%
COMPANY DESCRIPTION
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues. In addition, the company offers OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; OpeRATOR, an O-glycan-specific protease; ImpaRATOR, an O-glycan-dependent protease; OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; and GlycOCATCH, an affinity resin. Further, it provides GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a family of antibody products; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as SEQURNA RNase Inhibitor Thermostable. Additionally, the company offers antibodies, proteins, antigens, kits, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services. It serves biotech and pharmaceutical, contract research, and contract manufacturing companies. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.